Semaglutide is a GLP-1 receptor agonist originally approved for managing Type 2 diabetes. Recent clinical trials have shown its efficacy in weight loss, leading to its approval for chronic weight management in individuals with obesity. However, semaglutide use solely for weight loss has sparked debate within the medical community. This controversy encompasses several critical aspects, including regulatory approval and off-label use, the balance of efficacy versus potential risks, cost and accessibility, equity in resource allocation, and the broader implications of medicalizing obesity. The influence of pharmaceutical companies, the need for clear clinical practice guidelines, and patient expectations further complicate the landscape.
What is Semaglutide?
Semaglutide is a synthetic analog of the human glucagon-like peptide-1 (GLP-1) hormone that mimics its actions in the body. Chemically, it is a modified version of GLP-1 with an amino acid sequence that enhances its stability and prolongs its activity, allowing for less frequent dosing. Brand names including Ozempic, Rybelsus, and Wegovy represent Semaglutide on the market. The FDA has approved its use for managing Type 2 diabetes mellitus and for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
How Does Semaglutide Help in Weight Loss?
Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, play a crucial role in glucose metabolism by enhancing the glucose-dependent secretion of insulin from pancreatic beta cells and inhibiting glucagon release from alpha cells, thus lowering blood glucose levels postprandially (Holst, 2007). Additionally, semaglutide suppresses glucagon secretion and slows gastric emptying, which prolongs nutrient absorption and reduces postprandial glucose spikes (Davies et al., 2021; Kushner et al., 2020). Semaglutide also influences central nervous system pathways to reduce appetite and food intake (Blundell et al., 2017). GLP-1 receptors in the brain mediate this anorectic effect, particularly in the hypothalamus, which regulates hunger and satiety signals. Pharmacokinetically, semaglutide exhibits favorable absorption when administered subcutaneously, with a bioavailability of 89% (Kapitza et al., 2015). It has a large volume of distribution, reflecting its extensive tissue penetration, and is metabolized through proteolytic cleavage by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase (NEP). Semaglutide is primarily excreted via the urine and feces. The pharmacodynamics of semaglutide are characterized by a prolonged half-life of approximately one week, allowing for once-weekly dosing. The dose-response relationship demonstrates that higher doses produce greater reductions in HbA1c and body weight, with clinical effects sustained over long-term treatment (Davies et al., 2021).
What are the Health Benefits of Semaglutide?
Semaglutide has demonstrated significant benefits for weight loss and metabolic health in clinical trials. Patients treated with semaglutide have experienced considerable weight loss, with long-term use helping maintain it (Wilding et al., 2021). This weight reduction is complemented by improvements in metabolic health, including lower HbA1c levels, beneficial for individuals with prediabetes, and enhanced insulin sensitivity and glucose metabolism (Kushner et al., 2020). Additionally, semaglutide has been associated with reductions in cardiovascular risk factors, such as decreased blood pressure and cholesterol levels. This in turn may lower the risk of cardiovascular events in overweight and obsese individuals (Marso et al., 2016). The drug also enhances quality of life by improving physical functioning and mobility, which positively impacts mental health and self-esteem. Semaglutide’s appetite-regulating effects, mediated through GLP-1 receptors in the brain, help suppress appetite, reduce caloric intake, and improve adherence to dietary modifications (Blundell et al., 2017). Furthermore, semaglutide may alleviate obesity-related conditions like sleep apnea and osteoarthritis (Davies et al., 2021).
Who Could Look Into Using Semaglutide For Weight Loss?
Identifying candidates for using semaglutide for weight loss involves specific patient selection criteria and thorough risk assessment. Ideal candidates include adults with a body mass index (BMI) ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity, such as hypertension or type 2 diabetes (Wilding et al., 2021). Contraindications include a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and patients should be assessed for pancreatitis risk and gallbladder disease (Wilding et al., 2021). The recommended dosing schedule for weight loss starts at a low dose and gradually increasing to the target dose of 2.4 mg weekly. This allows the body to adapt and minimize side effects (Kushner et al., 2020). Transitioning from diabetes management to weight management requires adjusting the dose and monitoring blood glucose levels to avoid hypoglycemia. Monitoring guidelines include regular follow-up visits to assess weight loss progress, metabolic parameters, and side effects. Managing adverse reactions such as gastrointestinal symptoms involves dose adjustments and supportive measures. The patient’s response and tolerance to therapy should also shape treatment plans, with a focus on maintaining significant weight loss (Davies et al., 2021).
What are the Risks of Taking Semaglutide?
While semaglutide is effective for weight loss, it also includes several risks. Gastrointestinal side effects, including nausea, vomiting, diarrhea, and constipation, are common but typically mild to moderate and often decrease over time (Wilding et al., 2021). There is a small risk of developing pancreatitis, a serious inflammation of the pancreas, necessitating monitoring for related symptoms (Marso et al., 2016). Additionally, semaglutide may increase the risk of gallbladder disease, including gallstones, warranting vigilance for gallbladder-related symptoms (Kapitza et al., 2015). In animal studies, GLP-1 receptor agonists like semaglutide have been associated with thyroid C-cell tumors, although the relevance to humans remains unclear, thus requiring monitoring for thyroid abnormalities (Davies et al., 2021). Hypoglycemia is a potential risk, particularly in tandem with other glucose-lowering agents (Kushner et al., 2020). Gastrointestinal side effects may also lead to dehydration and acute kidney injury (Wilding et al., 2021). Injection site reactions, such as pain, redness, and swelling, are generally mild and transient. The high cost of semaglutide may limit accessibility for some patients, and insurance coverage for off-label use can be challenging. Lastly, the long-term safety profile of semaglutide requires further research to fully understand long-term risks and benefits (Davies et al., 2021).
What are Other Concerns Regarding Semaglutide?
The controversy surrounding the use of semaglutide for weight loss centers on several key issues. While semaglutide was originally approved for managing Type 2 diabetes, its approval for chronic weight management has sparked regulatory concerns when used solely for weight loss without diabetes (Wilding et al., 2021). Off-label use in non-diabetic patients raises questions about appropriateness and safety(Kushner et al., 2020). Potential risks like gastrointestinal issues, pancreatitis, and gallbladder disease create a debate about whether weight loss benefits outweigh these risks, especially for those without severe obesity (Kushner et al., 2020). Semaglutide’s high cost also limits accessibility and many ponder its use for weight loss compared to cheaper options (Kushner et al., 2020). Ethical concerns about distribution question whether using semaglutide only for weight loss limits those needing it for diabetes treatment.
What are Some Ethical Concerns With Semaglutide For Weight Loss?
The pharmaceutical approach to weight management may undermine efforts to promote sustainable lifestyle changes such as diet and exercise (Davies, et al., 2021). This medicalization of obesity, along with aggressive pharmaceutical marketing, raises ethical questions about commercial influences on prescribing practices. The long-term safety of semaglutide for weight loss is also still under investigation (Davies, et al., 2021). Integration into clinical practice varies, with professional organizations offering differing guidelines. Additionally, patients may have unrealistic expectations about weight loss outcomes due to marketing and anecdotal success stories. This in turn requires thorough patient education to manage expectations and ensure informed decision-making (Davies, et al., 2021).
Final Thoughts
While semaglutide has shown promise in weight loss and metabolic health improvements, its use for weight loss alone is controversial. The off-label application without specific FDA approval for non-diabetic patients raises regulatory and safety concerns. Despite the major weight loss benefits found in clinical trials, potential risks such as gastrointestinal issues, pancreatitis, and gallbladder disease are concerning. High cost and accessibility issues affect its availability. Ethical concerns about resource allocation and pharmaceutical marketing’s influence on prescribing practices further complicate semaglutide’s use.
Our catalog of CE courses offers further insights on topics such as diabetes and weight management.
Author: Jennifer Walker, RN, MSN, NPD-BC, GERO-BC, NE-BC
References:
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017). Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism, 19(9), 1242-1251.
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., … & Jabbour, S. (2021). Efficacy of once-weekly semaglutide versus placebo as adjunct to basal insulin in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. The Lancet Diabetes & Endocrinology, 9(7), 455-467.
Kapitza, C., Nosek, L., Jensen, L., Hartvig, H., Jensen, C. B., & Flint, A. (2015). Semaglutide, a once-weekly human GLP-1 analog, shows dose-dependent effects on glucose and body weight. Diabetes, Obesity and Metabolism, 17(5), 510-516.
Kushner, R. F., Calanna, S., Davies, M., Dicker, D., Garvey, W. T., Goldman, B., … & Wadden, T. (2020). Semaglutide 2.4 mg for the treatment of obesity in adults: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 22(9), 1772-1780.
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., … & Seufert, J. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834-1844.
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., … & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.
